
Humira: An injected biologic for moderate to severe plaque psoriasis. It blocks TNF, one of the main inflammation signals behind psoriasis, and is usually given as a shot under the skin every other week. Skyrizi: An injected biologic for moderate to severe plaque psoriasis. It blocks interleukin-23, a signal that sits high up in the psoriasis chain, and after two starting doses it is given about four times a year.


Choose for moderate to severe psoriasis or hidradenitis suppurativa — the first approved biologic for HS, now with cheaper biosimilars.
Choose for moderate to severe psoriasis when you want high clearance with only about four injections a year.
Can you take them together?
Two biologics are not used together, as this raises infection risk without proven benefit. Switch from one to the other instead.
Compare uses by strength of evidence. Evidence level describes confidence in a benefit, not its size.











Binds TNF: Captures an immune messenger that promotes inflammation. Reduces inflammatory signaling: TNF has less ability to activate its receptors. Lets inflamed skin settle: Conditions such as psoriasis can improve over time.
Adalimumab binds TNF-alpha and inhibits its interaction with p55/p75 TNF receptors. This image focuses on skin inflammation; Humira also has other indications.

Blocks IL-23: Binds this immune messenger before it reaches its receptor. Turns down inflammatory T cells: Reduces signals that keep the psoriasis cycle active. Helps plaques clear: Excess skin buildup and inflammation gradually decrease.
Risankizumab selectively targets the p19 subunit of IL-23, not IL-12. The T-cell and skin changes are a simplified downstream interpretation.
Adults are not dosed by body weight. You start with a larger loading dose to get levels up fast, then settle into an every-other-week rhythm.
Starting dose: 80 mg on day one, as one 80 mg injection or two 40 mg injections at different spots.
One week later: 40 mg.
Usual dose: 40 mg every other week, the same day of the week each time.
If it stops working: Some people move to weekly injections, others switch drugs. The prescriber's call.
Other conditions: Hidradenitis suppurativa uses a heavier loading dose and weekly maintenance, so do not assume a friend's schedule matches yours.
How long: Long term, with no set course length. It continues while it works and is tolerated.
Two starting doses close together, then a long steady interval. Not adjusted for body weight.
Starting dose: 150 mg as one injection.
Second dose: 150 mg, four weeks after the first.
Usual dose: 150 mg every 12 weeks — about four injections a year after the first year.
If it stops working: There is no approved higher dose or shorter interval for psoriasis. Losing response means reviewing the diagnosis, not injecting more often.
How long: Long term, with no set end point, while it works and is tolerated.
Any time of day, but pick a set day of the week and keep to it. Every other week is easy to lose track of, so set a phone reminder on day one.
Take the pen or syringe out of the fridge 15 to 30 minutes before injecting. Cold liquid stings more. Do not warm it in the microwave or hot water.
Inject into the front of the thigh or the belly, at least two inches from the navel. Rotate the spot each time, and avoid skin that is bruised, red, hard, tender or scarred. Never inject through a plaque. A nurse or pharmacist should train you in person for the first dose. Used pens go in a sharps container, never the household bin.
Any time of day. The calendar matters more here than with a weekly drug. Twelve weeks is long enough that people lose track, so put every dose date in your phone and book the next reminder the day you inject.
Take it out of the fridge 15 to 30 minutes before and let it warm on the counter. Cold liquid stings. No hot water, no microwave.
Inject into the front of the thigh or the belly, at least two inches from the navel. The back of the upper arm works if someone else is doing it. Rotate the site, avoid skin that is bruised, tender, hard or scarred, and never inject through a plaque. Ask for training before the first dose. Used devices go in a sharps container.
Inject as soon as you remember, then return to your original schedule rather than shifting future doses. Never inject two doses to catch up. If you have missed more than one dose, call the prescriber before restarting — long gaps can blunt how well it works.
Inject as soon as you remember, then count twelve weeks from that day. If it has been much longer than twelve weeks, call the prescriber first so the schedule can be reset.
Everyone is screened for tuberculosis before the first dose — a skin test or TB blood test, often with a chest X-ray. TNF blockers can wake a dormant TB infection, so a positive screen is treated first and adalimumab waits until that treatment is under way. Testing is often repeated yearly, or sooner if you live somewhere TB is common.
Hepatitis B and C are checked too, because hepatitis B can reactivate when the immune signal is blocked.
After that there is no fixed blood test schedule like methotrexate's. Many doctors check a blood count and liver tests occasionally. Most monitoring is clinical — how the skin looks, and whether you are getting more infections than usual.
Skin should be checked periodically, because TNF blockers are linked to a small increase in skin cancer. The label also carries a boxed warning about serious infections and about lymphoma and other cancers, based mostly on rare cases in children and young adults. The absolute risk is low, but it is why this prescription gets regular review.
Everyone is screened for tuberculosis before the first dose — a skin test or TB blood test, plus a chest X-ray if that is positive. Dormant TB is treated first. This class probably carries less TB risk than the TNF blockers, but screening is not optional.
Hepatitis B and C are usually checked at the same time.
After that there is no fixed blood test schedule. Risankizumab does not need the regular liver and blood count testing methotrexate does. Monitoring is clinical: the skin, whether infections are more frequent, whether the dose dates are kept. TB testing is repeated yearly or by exposure risk.
There is no boxed warning. The most common side effects reported are upper respiratory infections, headache, tiredness, fungal skin infections and injection site reactions. Serious allergic reactions are rare but are why the first dose is often given with someone trained nearby.
Approximate windows, not promises.
First few minutesThe injection: A sting for a few seconds. Injection site reactions, if they happen, show up in the first weeks.
First few minutesThe injection: A sharp sting for a few seconds, then redness or a small welt. Settles within a day or two.
Weeks 1 to 4Starting: Itching often eases before the plaques look different, and some people see the scale thin early.
Weeks 1 to 4Starting: Itch settles first. Scale lifts and plaques thin.
Weeks 4 to 12Working: Plaques flatten, scale lifts and redness fades from the middle outward. Most of the visible change happens here. Psoriatic arthritis improves on a similar timeline, and hidradenitis suppurativa settles to fewer painful lumps on its own heavier schedule.
Week 16Judge it here: The point the trials measured. Most people reached at least a 75 percent improvement in skin involvement and severity, and a smaller share cleared almost completely.
Week 16Judge it here: Most people reached 90 percent clearer skin, and many were clear or nearly clear. Joints improve on the same timeline.
Months 6 to 12Nails: The slowest, because a nail takes months to grow out. Pitting and lifting improve well after the skin has settled.
After the first yearLong term: Most people who respond keep responding.
Weeks 4 to 16Working: Most of the change happens here, from the second dose on. Plaques flatten and redness fades from the middle out, often leaving a paler or darker mark.
3 to 6 monthsScalp, palms and soles: Slower than the trunk and limbs.
6 to 12 monthsNails: Last to change, because a nail takes months to grow out.
Between dosesSteady state: Most people notice no dip. If plaques reliably return in the last few weeks, say so.
Sorted by what to do about them.
The list price is very high, tens of thousands of dollars a year. Almost nobody pays that. What you pay depends on your insurance, and getting there takes paperwork.
Prior authorization is close to universal. Most plans require you to have tried and failed something cheaper first — phototherapy, methotrexate or another systemic drug — and they want records to prove it.
Biosimilars changed the picture. Several have been sold in the United States since 2023, some at much lower list prices. Which one you get is usually decided by your plan's formulary, not your dermatologist, and plans switch year to year. A switch is a paperwork event, not a medical downgrade, though you may need retraining on a different pen.
Manufacturer copay cards can bring the cost down to very little with commercial insurance. By law they cannot be used with Medicare or Medicaid. For those plans, or with no insurance, manufacturer and foundation assistance programs are the usual route, and their rules change often.
The list price runs to tens of thousands of dollars a year. Almost nobody pays that; what you pay depends on your plan.
It is brand only — no generic, no biosimilar — so there is no cheaper equivalent to switch to. That is a real difference from adalimumab.
Prior authorization is close to universal. Most plans require documented failure of something cheaper first — phototherapy, methotrexate, sometimes another biologic. Denials are usually about missing records rather than the drug, and appeals succeed reasonably often when the history is documented.
Manufacturer copay cards can cut the cost to very little with commercial insurance. By law they cannot be used with Medicare or Medicaid. For those plans, or no insurance, the manufacturer's patient assistance program and independent foundations are the usual routes. Terms change often.
One practical note: because doses are twelve weeks apart, a change of insurance or a formulary switch in January can land in the middle of a dosing gap. Check coverage before the next dose is due, not the week it is.
A large protein grown in living cells rather than a factory chemical. That is why it is injected, and why it lives in the fridge.
A sharp sting for a few seconds. Letting it warm to room temperature first makes a real difference, and citrate-free versions sting less than the original.
Some change by 4 weeks, and about 16 weeks before you judge it fairly. If nothing has happened by then, talk about switching.
Yes, apart from live ones. The flu shot, COVID, pneumonia vaccines and Shingrix are fine and usually recommended. Have live vaccines before you start.
A simple cold is usually not a reason to skip a dose. Anything with a fever, or needing antibiotics, should be checked with the prescriber first.
It must be shown to have no clinically meaningful difference from the original. The pen changes; what is inside does the same job.
A large protein grown in living cells rather than a chemical made in a factory. That is why it is injected, and why it lives in the fridge.
After the first two doses, four weeks apart, yes. The drug stays in the body long enough that the gap can be twelve weeks.
A few seconds of stinging. Letting it warm to room temperature first makes a noticeable difference.
Tuberculosis and hepatitis before you start, and TB testing often repeated yearly. Beyond that, no routine schedule.
Inject when you remember and count twelve weeks from that day. If you are weeks or months late, call first.
Yes, apart from live ones. The flu shot, COVID vaccines and Shingrix are not live. Have any live ones before starting.